Insider · CIK 0001679132

NEWMAN MARY

Reports to the SEC for 1 company · SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001679132

Forms 4 and 5

Insider transactions

23 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2018-11-15	Audentes Therapeutics, Inc.A Award	SVP, Regulatory Affairs	AAward	+660 sh	$19.64	+$13K	660
2018-06-25	Audentes Therapeutics, Inc.M Exercise/Conversion	SVP, Regulatory Affairs	MExercise/Conversion	+8,245 sh	$2.19	+$18K	8,245
2018-06-25	Audentes Therapeutics, Inc.S Sale	SVP, Regulatory Affairs	SSale	−8,245 sh	$40.77	−$336K	0
2018-06-25	Audentes Therapeutics, Inc.M Exercise/Conversion	SVP, Regulatory Affairs	MExercise/Conversion	+300 sh	$2.19	+$655.56	300
2018-06-25	Audentes Therapeutics, Inc.S Sale	SVP, Regulatory Affairs	SSale	−300 sh	$41.37	−$12.4K	0
2018-06-25	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	SVP, Regulatory Affairs	MExercise/Conversion	−8,545 sh	—	—	15,272
2018-03-15	Audentes Therapeutics, Inc.M Exercise/Conversion	SVP, Regulatory Affairs	MExercise/Conversion	+4,076 sh	$2.19	+$8,926.44	4,076
2018-03-15	Audentes Therapeutics, Inc.S Sale	SVP, Regulatory Affairs	SSale	−4,076 sh	$29.66	−$121K	0
2018-03-15	Audentes Therapeutics, Inc.M Exercise/Conversion	SVP, Regulatory Affairs	MExercise/Conversion	+5,524 sh	$2.19	+$12.1K	5,524
2018-03-15	Audentes Therapeutics, Inc.S Sale	SVP, Regulatory Affairs	SSale	−5,524 sh	$30.79	−$170K	0
2018-03-15	Audentes Therapeutics, Inc.M Exercise/Conversion	SVP, Regulatory Affairs	MExercise/Conversion	+400 sh	$2.19	+$876	400
2018-03-15	Audentes Therapeutics, Inc.S Sale	SVP, Regulatory Affairs	SSale	−400 sh	$31.62	−$12.6K	0
2018-03-15	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	SVP, Regulatory Affairs	MExercise/Conversion	−10K sh	—	—	23,817
2017-11-16	Audentes Therapeutics, Inc.M Exercise/Conversion	SVP, Regulatory Affairs	MExercise/Conversion	+5,740 sh	$2.19	+$12.6K	5,740
2017-11-16	Audentes Therapeutics, Inc.S Sale	SVP, Regulatory Affairs	SSale	−5,740 sh	$26.49	−$152K	0
2017-11-16	Audentes Therapeutics, Inc.M Exercise/Conversion	SVP, Regulatory Affairs	MExercise/Conversion	+4,260 sh	$2.19	+$9,329.4	4,260
2017-11-16	Audentes Therapeutics, Inc.S Sale	SVP, Regulatory Affairs	SSale	−4,260 sh	$27.31	−$116K	0
2017-11-16	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	SVP, Regulatory Affairs	MExercise/Conversion	−10K sh	—	—	33,817
2017-11-16	Audentes Therapeutics, Inc.Stock Option (right to buy)A Award	SVP, Regulatory Affairs	AAward	+50K sh	—	—	50,000
2017-08-24	Audentes Therapeutics, Inc.M Exercise/Conversion	SVP, Regulatory Affairs	MExercise/Conversion	+10K sh	$2.19	+$21.9K	10,000
2017-08-24	Audentes Therapeutics, Inc.S Sale	SVP, Regulatory Affairs	SSale	−10K sh	$20.00	−$200K	0
2017-08-24	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	SVP, Regulatory Affairs	MExercise/Conversion	−10K sh	—	—	43,817
2017-01-25	Audentes Therapeutics, Inc.Stock Option (right to buy)A Award	SVP, Regulatory Affairs	AAward	+50K sh	—	—	50,000

Recent filings

Accepted (ET)
Nov 164
NEWMAN MARY0001209191-18-059059
SEC(opens sec.gov)
Jun 274
NEWMAN MARY0001209191-18-039711
SEC(opens sec.gov)
Apr 24
NEWMAN MARY0001209191-18-022600
SEC(opens sec.gov)
Nov 174
NEWMAN MARY0001209191-17-061542
SEC(opens sec.gov)
Aug 254
NEWMAN MARY0001209191-17-050294
SEC(opens sec.gov)

Companies

Audentes Therapeutics, Inc.SVP, Regulatory Affairs

Address

C/O AUDENTES THERAPEUTICS, INC. 600 CALIFORNIA STREET, 17TH FLOOR

SAN FRANCISCO, CA, 94108